Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
Public ClinicalTrials.gov record NCT00144300. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.
Study identification
- NCT ID
- NCT00144300
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 246 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2005 (Type not available)
- Primary completion
- Sep 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Mar 14, 2014
Started 2005
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 248.538.00007 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 248.538.00008 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 248.538.00021 Boehringer Ingelheim Investigational Site | Fountain Valley | California | — | — |
| 248.538.00022 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 248.538.00001 Boehringer Ingelheim Investigational Site | New Haven | Connecticut | — | — |
| 248.538.00002 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 248.538.00016 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 248.538.00023 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 248.538.00013 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 248.538.00009 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 248.538.00011 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 248.538.00005 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 248.538.00014 Boehringer Ingelheim Investigational Site | Southfield | Michigan | — | — |
| 248.538.00010 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.538.00015 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.538.00020 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.538.00012 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 248.538.00006 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 248.538.00004 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 248.538.00003 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 248.538.00017 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00144300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2014 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00144300 live on ClinicalTrials.gov.